Totality of evidence in the development of ABP 215, an approved bevacizumab biosimilar

Publication

Totality of evidence in the development of ABP 215, an approved bevacizumab biosimilar

Thomas, M
;
Thatcher, Nick
;
Goldschmidt, J
;
Ohe, Y
;
McBride, HJ
;
Hanes, V

Authors

Thomas, M
Thatcher, Nick
Goldschmidt, J
Ohe, Y
McBride, HJ
Hanes, V

Affiliation

Internistische Onkologie der Thoraxtumoren, Thoraxklinik im Universitatsklinikum Heidelberg, Translational Lung Research Center, Heidelberg, Germany

Date

2019

Collections

All Christie Publications

Show all metadata

Files

Full text, Open Access article

Adobe PDF, 2.13 MB

Type

Article

Citation

Thomas M, Thatcher N, Goldschmidt J, Ohe Y, McBride HJ, Hanes V. Totality of evidence in the development of ABP 215, an approved bevacizumab biosimilar. Immunotherapy. 2019;11(15):1337-51.

URI

http://hdl.handle.net/10541/622413